secwatch.observer — SEC 8-K summary
======================================

Issuer:     Spyre Therapeutics, Inc. (SYRE)
CIK:        0001636282
Form:       8-K
Filed at:   2023-01-18T23:59:59+00:00
Accession:  0000950170-23-000840
Event type: regulatory
Sentiment:  negative
Materiality: 0.65
Item codes: 3.01
LLM model:  deepseek-v4-flash:cloud@v2

Aeglea BioTherapeutics receives Nasdaq minimum bid price deficiency notice; 180-day cure period to July 12, 2023
--------------------------------------------------------------------------------

- Received Nasdaq notice on Jan 13, 2023 for closing bid price below $1.00 for 30 consecutive trading days.
- Must regain compliance by July 12, 2023 with bid price >= $1.00 for at least 10 consecutive days.
- If not compliant by July 12, may transfer to Nasdaq Capital Market for an additional 180-day cure period.
- No immediate effect on listing; company intends to monitor bid price and consider options.
- Failure to regain compliance could result in delisting subject to appeal rights.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1636282/000095017023000840/0000950170-23-000840-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1636282/000095017023000840/agle-20230113.htm
  HTML page:      https://secwatch.observer/filing/0000950170-23-000840

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer